DK0840607T3 - Ny medicinsk anvendelse - Google Patents

Ny medicinsk anvendelse

Info

Publication number
DK0840607T3
DK0840607T3 DK96918965T DK96918965T DK0840607T3 DK 0840607 T3 DK0840607 T3 DK 0840607T3 DK 96918965 T DK96918965 T DK 96918965T DK 96918965 T DK96918965 T DK 96918965T DK 0840607 T3 DK0840607 T3 DK 0840607T3
Authority
DK
Denmark
Prior art keywords
pct
medical application
new medical
sec
date
Prior art date
Application number
DK96918965T
Other languages
English (en)
Inventor
Lars Faendriks
Anders Pettersson
Original Assignee
Pharmacore Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacore Ab filed Critical Pharmacore Ab
Application granted granted Critical
Publication of DK0840607T3 publication Critical patent/DK0840607T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96918965T 1995-06-19 1996-06-10 Ny medicinsk anvendelse DK0840607T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502219A SE9502219D0 (sv) 1995-06-19 1995-06-19 Novel medical use
PCT/SE1996/000758 WO1997000070A1 (en) 1995-06-19 1996-06-10 Novel medical use

Publications (1)

Publication Number Publication Date
DK0840607T3 true DK0840607T3 (da) 2002-05-06

Family

ID=20398663

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918965T DK0840607T3 (da) 1995-06-19 1996-06-10 Ny medicinsk anvendelse

Country Status (27)

Country Link
US (1) US6096772A (da)
EP (1) EP0840607B1 (da)
JP (1) JPH11507921A (da)
KR (1) KR19990023021A (da)
CN (1) CN1091595C (da)
AT (1) ATE214925T1 (da)
AU (1) AU706660B2 (da)
BR (1) BR9608472A (da)
CA (1) CA2225175A1 (da)
CZ (1) CZ289400B6 (da)
DE (1) DE69620186T2 (da)
DK (1) DK0840607T3 (da)
EE (1) EE03385B1 (da)
ES (1) ES2173294T3 (da)
HU (1) HUP9901448A3 (da)
IL (1) IL122659A (da)
IS (1) IS4619A (da)
MY (1) MY114716A (da)
NO (1) NO975922D0 (da)
NZ (1) NZ310606A (da)
PT (1) PT840607E (da)
RU (1) RU2209064C2 (da)
SE (1) SE9502219D0 (da)
SK (1) SK172197A3 (da)
UA (1) UA55387C2 (da)
WO (1) WO1997000070A1 (da)
ZA (1) ZA964690B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6602248B1 (en) 1995-06-07 2003-08-05 Arthro Care Corp. Methods for repairing damaged intervertebral discs
US7393351B2 (en) 1995-06-07 2008-07-01 Arthrocare Corporation Apparatus and methods for treating cervical inter-vertebral discs
US20050004634A1 (en) 1995-06-07 2005-01-06 Arthrocare Corporation Methods for electrosurgical treatment of spinal tissue
US7357798B2 (en) 1996-07-16 2008-04-15 Arthrocare Corporation Systems and methods for electrosurgical prevention of disc herniations
US6620155B2 (en) 1996-07-16 2003-09-16 Arthrocare Corp. System and methods for electrosurgical tissue contraction within the spine
US6726684B1 (en) 1996-07-16 2004-04-27 Arthrocare Corporation Methods for electrosurgical spine surgery
SE9800550D0 (sv) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
US20030158545A1 (en) 2000-09-28 2003-08-21 Arthrocare Corporation Methods and apparatus for treating back pain
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
AU2002362310A1 (en) 2001-09-14 2003-04-01 Arthrocare Corporation Methods and apparatus for treating intervertebral discs
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
SI1589966T1 (sl) * 2003-01-30 2011-06-30 Lek Pharmaceuticals D.D. Postopek čiščenja losartana
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US8979838B2 (en) 2010-05-24 2015-03-17 Arthrocare Corporation Symmetric switching electrode method and related system
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
GB2263638A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB2263635A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Also Published As

Publication number Publication date
EE03385B1 (et) 2001-04-16
ATE214925T1 (de) 2002-04-15
DE69620186T2 (de) 2002-10-31
SK172197A3 (en) 1998-07-08
NZ310606A (en) 2001-03-30
IS4619A (is) 1997-11-25
ZA964690B (en) 1996-12-19
BR9608472A (pt) 1998-12-29
DE69620186D1 (de) 2002-05-02
CN1192681A (zh) 1998-09-09
IL122659A0 (en) 1998-08-16
JPH11507921A (ja) 1999-07-13
EE9700366A (et) 1998-06-15
US6096772A (en) 2000-08-01
MY114716A (en) 2002-12-31
IL122659A (en) 2003-01-12
PT840607E (pt) 2002-09-30
UA55387C2 (uk) 2003-04-15
EP0840607B1 (en) 2002-03-27
WO1997000070A1 (en) 1997-01-03
NO975922L (no) 1997-12-16
ES2173294T3 (es) 2002-10-16
SE9502219D0 (sv) 1995-06-19
RU2209064C2 (ru) 2003-07-27
CN1091595C (zh) 2002-10-02
CA2225175A1 (en) 1997-01-03
MX9710002A (es) 1998-07-31
NO975922D0 (no) 1997-12-16
HK1010152A1 (en) 1999-06-17
HUP9901448A2 (hu) 2000-04-28
AU1184097A (en) 1997-01-15
AU706660B2 (en) 1999-06-17
EP0840607A1 (en) 1998-05-13
CZ289400B6 (cs) 2002-01-16
CZ373097A3 (cs) 1998-05-13
HUP9901448A3 (en) 2002-03-28
KR19990023021A (ko) 1999-03-25

Similar Documents

Publication Publication Date Title
NO975922D0 (no) Ny medisinsk anvendelse
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
DK0706378T3 (da) Ny farmaceutisk formulering.
GR3036745T3 (en) New pharmaceutical preparation for pain management
BR9407748A (pt) Formulação farmacéutica processo para preparação da mesma e processo para a prevenção e/ou o tratamento de neurodegeneração ou para a obtenção de um efeito anti-convulsivo ou sedação em um paciente
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
SE9600120D0 (sv) Novel medical use
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
SE9402880D0 (sv) New peptide derivatives
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
SE9504267D0 (sv) New therapeutic use
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
FR2718965B1 (fr) Nouvelle application thérapeutique de la spiramycine.
ZA9427B (en) Use of riluzole for promoting restoration following radiation
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту